Literature DB >> 31439582

Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.

Reinout H de Roest1, Steven W Mes1, Jos B Poell1, Arjen Brink1, Mark A van de Wiel2,3, Elisabeth Bloemena4,5, Elena Thai6, Tito Poli7, C René Leemans1, Ruud H Brakenhoff8.   

Abstract

PURPOSE: To investigate the pathobiological origin of local relapse after chemoradiotherapy, we studied genetic relationships of primary tumors (PT) and local relapses (LR) of patients treated with chemoradiotherapy. EXPERIMENTAL
DESIGN: First, low-coverage whole genome sequencing was performed on DNA from 44 biopsies of resected head and neck squamous cell carcinoma (HNSCC) specimens (median 3 biopsies/tumor) to assess suitability of copy number alterations (CNAs) as biomarker for genetic relationships. CNAs were compared within and between tumors and an algorithm was developed to assess genetic relationships with consideration of intratumor heterogeneity. Next, this CNA-based algorithm was combined with target enrichment sequencing of genes frequently mutated in HNSCC to assess the genetic relationships of paired tumors and LRs of patients treated with chemoradiotherapy.
RESULTS: Genetic relationship analysis using CNAs could accurately (96%) predict tumor biopsy pairs as patient-matched or independent. However, subsequent CNA analysis of PTs and LRs after chemoradiotherapy suggested genetic relationships in only 20% of cases, and absence in 80%. Target enrichment sequencing for mutations confirmed absence of any genetic relationship in half of the paired PTs and LRs.
CONCLUSIONS: There are minor variations in CNA profiles within different areas of HNSCC tumors and many between independent tumors, suggesting that CNA profiles could be exploited as a marker of genetic relationship. Using CNA profiling and mutational analysis of cancer driver genes, relapses after chemoradiotherapy appear to be partially genetically related to the corresponding PTs, but seem often genetically unrelated. This remarkable observation warrants further studies and will impact therapeutic innovations and prognostic modeling when using index tumor characteristics. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31439582     DOI: 10.1158/1078-0432.CCR-19-0628

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  SOD2- and NRF2-associated Gene Signature to Predict Radioresistance in Head and Neck Cancer.

Authors:  Joo Kyung Noh; Seon Rang Woo; Miyong Yun; Min Kyeong Lee; Moonkyoo Kong; Soonki Min; Su Il Kim; Young Chan Lee; Young-Gyu Eun; Seong-Gyu Ko
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

2.  Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy.

Authors:  Simon Keek; Sebastian Sanduleanu; Frederik Wesseling; Reinout de Roest; Michiel van den Brekel; Martijn van der Heijden; Conchita Vens; Calareso Giuseppina; Lisa Licitra; Kathrin Scheckenbach; Marije Vergeer; C René Leemans; Ruud H Brakenhoff; Irene Nauta; Stefano Cavalieri; Henry C Woodruff; Tito Poli; Ralph Leijenaar; Frank Hoebers; Philippe Lambin
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

3.  Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition.

Authors:  Anne M van Harten; D Vicky de Boer; Sanne R Martens-de Kemp; Marijke Buijze; Sonja H Ganzevles; Keith D Hunter; C René Leemans; Victor W van Beusechem; Rob M F Wolthuis; Renée X de Menezes; Ruud H Brakenhoff
Journal:  Sci Rep       Date:  2020-02-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.